Physicochemical Properties
| Molecular Formula | C13H8N2O2S |
| Molecular Weight | 256.279821395874 |
| Exact Mass | 256.03 |
| CAS # | 1954650-11-3 |
| PubChem CID | 124141953 |
| Appearance | Light brown to brown solid powder |
| LogP | 2.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 18 |
| Complexity | 404 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S1C(C2C=CC=CC=2)=CC2C(NC(C(C1=2)=N)=O)=O |
| InChi Key | CQHAROORCYWRRH-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C13H8N2O2S/c14-10-11-8(12(16)15-13(10)17)6-9(18-11)7-4-2-1-3-5-7/h1-6,14H,(H,15,16,17) |
| Chemical Name | 7-imino-2-phenylthieno[3,2-c]pyridine-4,6-dione |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase. J Pharmacol Exp Ther. 2019 Dec;371(3):652-662. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~10 mg/mL (~39.02 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (3.90 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9020 mL | 19.5099 mL | 39.0198 mL | |
| 5 mM | 0.7804 mL | 3.9020 mL | 7.8040 mL | |
| 10 mM | 0.3902 mL | 1.9510 mL | 3.9020 mL |